Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Q32 Bio Inc. (QTTB)
Price$11.99Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $1.2M | $3.2M | $34.0M | $2.7M | $1.7M | $5.3M | — |
| Research & development | $19.2M | $48.1M | $31.7M | $98.4M | $93.1M | $100.4M | $89.4M | $47.9M | $21.4M |
| Operating expenses | $36.8M | $66.1M | $41.6M | $136.5M | $129.9M | $133.0M | $111.6M | $65.2M | $29.7M |
| Operating income | $16.9M | −$66.1M | −$48.3M | −$133.3M | −$95.9M | −$130.3M | −$109.9M | −$59.9M | −$29.7M |
| Operating margin | 31.45% | — | −4,174.31% | −4,154.64% | −282.44% | −4,820.98% | −6,599.22% | −1,126.01% | — |
| EBITDA | $17.3M | −$65.6M | −$47.8M | −$132.0M | −$87.6M | −$122.3M | −$103.6M | −$58.6M | −$29.0M |
| EBITDA margin | 32.18% | — | −4,131.14% | −4,114.34% | −257.86% | −4,526.20% | −6,219.99% | −1,101.79% | — |
| Net income | $29.8M | −$47.7M | −$53.7M | −$5.0M | −$95.8M | −$128.7M | −$103.9M | −$55.6M | −$30.0M |
| Net profit margin | 55.49% | — | −4,649.05% | −156.02% | −281.90% | −4,762.92% | −6,237.45% | −1,044.29% | — |
| Basic EPSper basic share | $0.00 | -$0.01 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
| Diluted EPSper diluted share | $0.00 | -$6.58 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
Owners
Reported shareholders
17.39%of listed shares
ORBIMED ADVISORS LLC4.13M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ORBIMED ADVISORS LLC | 17.39%4.13M shares |
Xu Diyong | ≈17.39%4.13M shares |
Boxer Capital Management, LLC | 13.27%3.15M shares |
Atlas Venture Life Science Advisors, LLC | 11.45%2.72M shares |
BVF INC/IL | 9.90%2.35M shares |
RA CAPITAL MANAGEMENT, L.P. | 9.83%2.33M shares |
Point72 Asset Management, L.P. | 4.94%1.17M shares |
Opaleye Management Inc. | 3.92%931K shares |
Logos Global Management LP | 3.37%800K shares |
SummitTX Capital, L.P. | 3.09%733.77K shares |
Atlas Venture Associates Opportunity III, L.P. / Atlas Venture Opportunity Fund Ill, L.P. / Atlas Venture Associates Opportunity III, LLC | ≈2.63%625K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.19%518.8K shares |
Ikarian Capital, LLC | 1.81%430K shares |
Woodline Partners LP | 1.21%286.21K shares |
AMERICAN CENTURY COMPANIES INC | 1.15%272.75K shares |
Sanofi | 1.03%244.08K shares |
ACADIAN ASSET MANAGEMENT LLC | 0.92%218.23K shares |
ACORN CAPITAL ADVISORS, LLC | 0.91%216.17K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.76%179.6K shares |
JANE STREET GROUP, LLC | 0.69%162.75K shares |
Percentages use 23.74M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 28, 2026Form 4 | Xu DiyongDirector,TenPercentOwner | BuyCommon Stock · indirect | 625.0K | $8.00 | $5.00M | 625.0K |
| May 28, 2026Form 4 | Xu DiyongDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.25M | $8.00 | $10.00M | 3.50M |
| May 28, 2026Form 4 | OrbiMed Capital GP VII LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 625.0K | $8.00 | $5.00M | 625.0K |
| May 28, 2026Form 4 | OrbiMed Capital GP VII LLC +2Director,TenPercentOwner | BuyCommon Stock · indirect | 1.25M | $8.00 | $10.00M | 3.50M |
| Feb 25, 2026Form 4 | Kalowski LeeCFO and President | SellCommon Stock | 4.0K | $4.51 | $18.0K | 35.9K |
Community posts
Q32 reports maintained hair-growth responses after treatment withdrawal
Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered fo ...
